Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services

INTRODUCTION: Replacement therapy is constantly required by Hemophilia A (HA) patients lacking coagulation factor VIII (FVIII). The most serious complication of this treatment is the development of neutralizing antibodies (inhibitors). AIM: The aim of this study is to determine the frequency of FVII...

Descripción completa

Detalles Bibliográficos
Autores principales: Oudat, Raida, Al-Maharmeh, Muna, Al-Ghrayeb, Rasha, Ogeilat, Tunia, Mustafa, Maher Kh.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical Sciences of Bosnia and Herzegovina 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406006/
https://www.ncbi.nlm.nih.gov/pubmed/32801433
http://dx.doi.org/10.5455/medarh.2020.74.187-190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406006/
https://www.ncbi.nlm.nih.gov/pubmed/32801433
http://dx.doi.org/10.5455/medarh.2020.74.187-190

Ejemplares similares